FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Marta Boffito

Research Profile

Disorders

HIV Infections

Chemicals & Drugs

Procedures

Physiology

Drug Interactions

Living Beings

Concepts & Ideas

Co-author Network

Publications

TOP 3
Peter Hayes; Akil Jackson; Jakub Kopycinski; Angela Lombardo; Eddy Sayeed; Andrea von Lieven; Devika Zachariah; James Ackland; Galit Alter; Marta Boffito; Hannah Cheeseman; Amy Chung; Lorna Clark; Josephine H Cox; Len Dally; Patricia E Fast; Brian Gazzard; Dilbinder Gill; Jill Gilmour; Dagna Laufer
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
Alessandro Schipani; Laura Dickinson; Saye Khoo; Andrew Owen; Rupert Austin; David Back; Marta Boffito; Gerry Davies
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
Marco Siccardi; Christoph Wyen; Lisa M Almond; Marta Boffito; N H Brockmeyer; Chantal Csajka; Catia Marzolini; A Owen; A Schipani; D Back
Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Marta Boffito (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Peter Hayes; Akil Jackson; Jakub Kopycinski; Angela Lombardo; Eddy Sayeed; Andrea von Lieven; Devika Zachariah; James Ackland; Galit Alter; Marta Boffito; Hannah Cheeseman; Amy Chung; Lorna Clark; Josephine H Cox; Len Dally; Patricia E Fast; Brian Gazzard; Dilbinder Gill; Jill Gilmour; Dagna Laufer
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
Clinical and vaccine immunology : CVI 2013;20(3):397-408.
2013: Alessandro Schipani; Laura Dickinson; Saye Khoo; Andrew Owen; Rupert Austin; David Back; Marta Boffito; Gerry Davies
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
Journal of acquired immune deficiency syndromes (1999) 2013;62(1):60-6.
2012: Marco Siccardi; Christoph Wyen; Lisa M Almond; Marta Boffito; N H Brockmeyer; Chantal Csajka; Catia Marzolini; A Owen; A Schipani; D Back
Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.
Clinical pharmacology and therapeutics 2012;92(4):494-502.
2012: Mohammed Lamorde; Jonathan Mayito; David Back; Marta Boffito; Pauline Byakika-Kibwika; Saye Khoo; Lillian Nabukeera; Jasper W Ogwal-Okeng; Mairin Ryan; John Tjia; Concepta Merry
Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.
Journal of acquired immune deficiency syndromes (1999) 2012;60(3):295-8.
2012: Mona Arab-Alameddine; Marta Boffito; Thierry Buclin; Matthias Cavassini; Chantal Csajka; Laurent A Decosterd; Julia di Iulio; Aurélie Fayet-Mello; Huldrych Günthard; Rubin Lubomirov; Michael Neely; Andrew Owen; Katharina Rentsch; Margalida Rotger; Amalio Telenti; Manel Aouri
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Antimicrobial agents and chemotherapy 2012;56(6):2959-66.
2012: Laura J Else; Sean Emery; Paul Fahey; Andrew Hill; Akil Jackson; Saye Khoo; Enmoore Lin; Rebekah Puls; Marco Siccardi; John Tjia; Victoria Watson; Alieu Amara; David J Back; Marta Boffito
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.
Antimicrobial agents and chemotherapy 2012;56(3):1427-33.
2012: Alessandro Schipani; Mike Youle; David J Back; Marta Boffito; Gerry Davies; Laura Dickinson; Deirdre Egan; Saye H Khoo; Andrew Owen
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.
Antiviral therapy 2012;17(5):861-8.
2012: Mohammed Lamorde; Mairin Ryan; William S Tamale; John Tjia; Alieu Amara; David Back; Marta Boffito; Pauline Byakika-Kibwika; Saye Khoo; Cissy Kityo; Francis Kiweewa; Concepta Merry
Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults.
AIDS research and treatment 2012;2012():105980.
2012: Akil Jackson; Saye Khoo; Graeme Moyle; Jessica Taylor; George Abongomera; David Back; Laura Dickinson; Brian Gazzard; Keerti Gedela; Marta Boffito
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
Antiviral therapy 2012;17(1):19-24.
2011: Andrew Hill; Saye Khoo; Marta Boffito; David Back
Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?
Journal of acquired immune deficiency syndromes (1999) 2011;58(5):e137-8.
2011: Akil Jackson; Saye Khoo; Neill Liptrott; Victoria Watson; Deidre Egan; Brian Gazzard; Keerti Gedela; Chris Higgs; Riaz Abbas; David Back; Marta Boffito
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
Journal of acquired immune deficiency syndromes (1999) 2011;58(5):450-7.
2011: Xiaodong Wang; Yaoshi Wu; Jenny Zhang; Li Zhu; Marta Boffito; Michael Child; Ellen Chung; Angela Kashuba; Lisa Mahnke; Kristine Patterson; Pablo Tebas; Richard Bertz
Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
AIDS patient care and STDs 2011;25(9):509-15.
2011: Marta Boffito; Brian Gazzard; Christopher Higgs; Akil Jackson; Saye Khoo; Alieu Amara; David Back; Natalia Seymour; Graeme Moyle
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
Antimicrobial agents and chemotherapy 2011;55(9):4218-23.
2011: Rebecca C Robey; Rhonda Meys; Salvinia Mletzko; Mark Nelson; Marta Boffito; Mark Bower; Christopher B Bunker; Frances M Gotch
Ex-vivo recognition of late-lytic CD8 epitopes specific for Kaposi's sarcoma-associated herpesvirus (KSHV) by HIV/KSHV-coinfected individuals.
Viral immunology 2011;24(3):211-20.
2011: Laura Dickinson; Marta Boffito; David Back; Laura Else; Nils von Hentig; Geraint Davies; Saye Khoo; Anton Pozniak; Graeme Moyle; Leon Aarons
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.
Antimicrobial agents and chemotherapy 2011;55(6):2775-82.
2011: Akil Jackson; Antonio D'Avolio; Victoria Watson; Stefano Bonora; David Back; Jessica Taylor; Kostantinos Armenis; Brian Gazzard; Graeme Moyle; Marta Boffito
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.
The Journal of antimicrobial chemotherapy 2011;66(4):885-9.
2011: Akil Jackson; Andrew Hill; Rebekah Puls; Laura Else; Janaki Amin; David Back; Enmoore Lin; Saye Khoo; Sean Emery; Roland Morley; Brian Gazzard; Marta Boffito
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.
The Journal of antimicrobial chemotherapy 2011;66(3):635-40.
2011: Pauline Byakika-Kibwika; Elly Katabira; Saye Khoo; Mohammed Lamorde; Peter Lwabi; Harriet Mayanja-Kizza; David Back; Marta Boffito; Wilson B Nyakoojo; Violet Okaba-Kayom; Concepta Merry
Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults.
Chemotherapy research and practice 2011;2011():393976.
2011: Mohammed Lamorde; Pauline Byakika-Kibwika; Violet Okaba-Kayom; Mairin Ryan; Peter Coakley; Marta Boffito; Rhoda Namakula; Francis Kalemeera; Robert Colebunders; David Back; Saye Khoo; Concepta Merry
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.
The Journal of antimicrobial chemotherapy 2011;66(1):180-3.
2010: Mohammed Lamorde; Pauline Byakika-Kibwika; Violet Okaba-Kayom; John P Flaherty; Marta Boffito; Rhoda Namakula; Mairin Ryan; Clemensia Nakabiito; David J Back; Saye Khoo; Concepta Merry; Kimberly K Scarsi
Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.
Journal of acquired immune deficiency syndromes (1999) 2010;55(3):345-50.
2010: Graeme Moyle; Marta Boffito; Albrecht Stoehr; Armin Rieger; Zancong Shen; Kimberly Manhard; Beth Sheedy; Vijay Hingorani; Anneke Raney; Mai Nguyen; Tranh Nguyen; Voon Ong; Li-Tain Yeh; Barry Quart
Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.
Antimicrobial agents and chemotherapy 2010;54(8):3170-8.
2010: Saliha Yilmaz; Marta Boffito; Sophie Collot-Teixeira; Ferruccio De Lorenzo; Laura Waters; Carl Fletcher; David Back; Anton Pozniak; Brian Gazzard; John L McGregor
Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays.
Genomics 2010;96(1):57-65.
2010: Paul A Randell; Akil G Jackson; Marta Boffito; David J Back; John F Tjia; Jessica Taylor; Sundhiya Mandalia; Graeme J Moyle
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Antiviral therapy 2010;15(8):1125-32.
2009: Andrew Hill; Jasper van der Lugt; Will Sawyer; Marta Boffito
How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials.
AIDS (London, England) 2009;23(17):2237-45.
2009: Marta Boffito; Akil Jackson; Mohammed Lamorde; David Back; Victoria Watson; Jessica Taylor; Laura Waters; David Asboe; Brian Gazzard; Anton Pozniak
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.
Journal of acquired immune deficiency syndromes (1999) 2009;52(2):222-7.
2009: mark bower; Justin Weir; Nicholas Francis; Tom Newsom-Davis; Sam Powles; Tim Crook; Marta Boffito; Brian Gazzard; Mark Nelson
The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.
AIDS (London, England) 2009;23(13):1701-6.
2009: Laura Dickinson; Marta Boffito; David Back; Laura Waters; Laura Else; Geraint Davies; Saye Khoo; Anton Pozniak; Leon Aarons
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
The Journal of antimicrobial chemotherapy 2009;63(6):1233-43.
2009: Graeme Moyle; Marta Boffito; Carl Fletcher; Christopher Higgs; Phillip E Hay; Ivy H Song; Yu Lou; Geoffrey J Yuen; Sherene S Min; Elena Guerini
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
Antimicrobial agents and chemotherapy 2009;53(4):1532-8.
2009: Graeme Moyle; Edwin DeJesus; Marta Boffito; Rebecca S Wong; Colleen Gibney; Karin Badel; Ron MacFarland; Gary Calandra; Gary Bridger; Stephen Becker
Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(6):798-805.
2009: Katherine M Coyne; Anton L Pozniak; Mohammed Lamorde; Marta Boffito
Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents.
AIDS (London, England) 2009;23(4):437-46.
2009: Jesse Soodalter; Marta Sousa; Marta Boffito
Drug-drug interactions involving new antiretroviral drugs and drug classes.
Current opinion in infectious diseases 2009;22(1):18-27.
2009: Ferruccio De Lorenzo; Marta Boffito; Sophie Collot-Teixeira; Brian Gazzard; John L McGregor; Kevin Shotliff; Han Xiao
Prevention of atherosclerosis in patients living with HIV.
Vascular health and risk management 2009;5(1):287-300.
2008: Laura Dickinson; Marta Boffito; David J Back; Saye H Khoo; Anton L Pozniak; Peter Mugyenyi; Concepta Merry; Reshma Saskia Autar; David Burger; Leon J Aarons
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.
The Journal of antimicrobial chemotherapy 2008;62(6):1344-55.
2008: Marta Boffito; Diego Miralles; Andrew Hill
Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
HIV clinical trials 2008;9(6):418-27.
2008: Marta Sousa; Anton Pozniak; Marta Boffito
Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs.
The Journal of antimicrobial chemotherapy 2008;62(5):872-8.
2008: Pauline Byakika-Kibwika; Mohammed Lamorde; Francis Kalemeera; Antonio D'Avolio; Sciandra Mauro; Giovanni Di Perri; Mairin Ryan; Harriet Mayanja-Kizza; Saye Khoo; David Back; Marta Boffito; Concepta Merry
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.
The Journal of antimicrobial chemotherapy 2008;62(5):1113-7.
2008: Monika Schöller-Gyüre; Marta Boffito; Anton L Pozniak; Ruud Leemans; Thomas N Kakuda; Brian Woodfall; Veerle Vyncke; Monika Peeters; Kati Vandermeulen; Richard Hoetelmans
Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
Pharmacotherapy 2008;28(10):1215-22.
2008: Laura Dickinson; Marta Boffito; Saye H Khoo; Malte Schutz; Leon J Aarons; Anton L Pozniak; David J Back
Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing.
The Journal of antimicrobial chemotherapy 2008;62(1):161-7.
2008: K Singh; L Dickinson; A Chaikan; D Back; C Fletcher; Anton Pozniak; G Moyle; Mark Nelson; Brian Gazzard; D Herath; Marta Boffito
Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.
Clinical pharmacology and therapeutics 2008;83(6):867-72.
2008: Anton L Pozniak; Marta Boffito; Deborah Russell; Caroline E Ridgway; Gary J Muirhead
A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
British journal of clinical pharmacology 2008;65 Suppl 1():54-9.
2008: Marta Boffito; Samantha Abel
A review of the clinical pharmacology of maraviroc. Introduction.
British journal of clinical pharmacology 2008;65 Suppl 1():1-4.
2008: Marta Boffito; Laura Else; David Back; Jessica Taylor; Saye Khoo; Marta Sousa; Anton Pozniak; Brian Gazzard; Graeme Moyle
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Antiviral therapy 2008;13(7):901-7.
2007: Katherine M Coyne; Marta Boffito; Nick Theobald; David Asboe
Simvastatin co-prescribed with protease inhibitors despite dangerous drug interactions.
Sexually transmitted infections 2007;83(6):498.
2007: Stephen Taylor; Marta Boffito; Saye Khoo; Erasmus Smit; David Back
Stopping antiretroviral therapy.
AIDS (London, England) 2007;21(13):1673-82.
2007: Marta Boffito; Alan Winston; Akil Jackson; Carl Fletcher; Anton Pozniak; Mark Nelson; Graeme Moyle; Izabela Tolowinska; Richard Hoetelmans; Diego Miralles; Brian Gazzard
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
AIDS (London, England) 2007;21(11):1449-55.
2007: Marta Boffito
Pharmacokinetics and pharmacodynamics in HAART and antibiotic therapy.
The new microbiologica 2007;30(3):346-9.
2007: Laura Dickinson; David Back; Anton Pozniak; Saye Khoo; Marta Boffito
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.
Therapeutic drug monitoring 2007;29(3):361-7.
2007: Lauro J Waters; Graeme Moyle; Stefano Bonora; Antonio D'Avolio; Laura Else; Sundhiya Mandalia; Anton Pozniak; Mark Nelson; Brian Gazzard; David Back; Marta Boffito
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Antiviral therapy 2007;12(5):825-30.
2006: Brian Gazzard; A J Bernard; Marta Boffito; Duncan Churchill; S Edwards; N Fisher; Anna Maria Geretti; Margaret Johnson; Clifford Leen; B Peters; Anton Pozniak; J Ross; John Walsh; Edmund Wilkins; Mike Youle
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).
HIV medicine 2006;7(8):487-503.
2006: Jennifer Ford; Marta Boffito; Desmond Maitland; Andrew Hill; David Back; Saye Khoo; Mark Nelson; Graeme Moyle; Brian Gazzard; Anton Pozniak
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
The Journal of antimicrobial chemotherapy 2006;58(5):1009-16.
2006: Marta Boffito; Deenan Pillay; Edmund Wilkins
Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies.
International journal of clinical practice 2006;60(9):1098-106.
2006: Marta Boffito; Desmond Maitland; Laura Dickinson; David Back; Andrew Hill; Carl Fletcher; Graeme Moyle; Mark Nelson; Brian Gazzard; Anton Pozniak
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
AIDS research and human retroviruses 2006;22(8):749-56.
2006: Alan Winston; David Back; Carl Fletcher; Lesley Robinson; Jennifer Unsworth; Izabela Tolowinska; Malte Schutz; Anton L Pozniak; Brian Gazzard; Marta Boffito
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
AIDS (London, England) 2006;20(10):1401-6.
2006: Alan Winston; Patrick W G Mallon; Marta Boffito
The clinical pharmacology of antiretrovirals in development.
Expert opinion on drug metabolism & toxicology 2006;2(3):447-58.
2006: Julie Fox; Marta Boffito; Alan Winston
The clinical implications of antiretroviral pharmacogenomics.
Pharmacogenomics 2006;7(4):587-96.
2006: Alan Winston; Nimesh Patel; David Back; Saye Khoo; Steve Bulbeck; Sundhiya Mandalia; Anton L Pozniak; Mark Nelson; Graeme Moyle; Brian Gazzard; Marta Boffito
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.
Journal of acquired immune deficiency syndromes (1999) 2006;41(5):675-6.
2006: Marta Boffito; Desmond Maitland; Anton Pozniak
Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies.
Journal of clinical pharmacology 2006;46(2):130-9.
2005: Marta Boffito; Alan Winston; Andrew Owen
Host determinants of antiretroviral drug activity.
Current opinion in infectious diseases 2005;18(6):543-9.
2005: Reshma Saskia Autar; Marta Boffito; Elly A M Hassink; Ferdinand W N M Wit; Jintanat Ananworanich; Umaporn Siangphoe; Anton Pozniak; David A Cooper; Praphan Phanuphak; Joep M A Lange; Kiat Ruxrungtham; David Burger
Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients.
The Journal of antimicrobial chemotherapy 2005;56(5):908-13.
2005: Marta Boffito; Anton Pozniak; Brian P Kearney; Christopher Higgs; Anita Mathias; Lijie Zhong; Jaymin Shah
Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.
Antimicrobial agents and chemotherapy 2005;49(10):4386-9.
2005: Daniel González de Requena; Stefano Bonora; Silvia Garazzino; Mauro Sciandra; Antonio D'Avolio; Riccardo Raiteri; R Marrone; Marta Boffito; francesco giuseppe de rosa; Alessandro Sinicco; Giovanni Di Perri
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.
Antimicrobial agents and chemotherapy 2005;49(9):3966-9.
2005: Desmond Maitland; Graeme Moyle; James Hand; Sundhiya Mandalia; Marta Boffito; Mark Nelson; Brian Gazzard
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
AIDS (London, England) 2005;19(11):1183-8.
2005: Alan Winston; Marta Boffito
The management of HIV-1 protease inhibitor pharmacokinetic interactions.
The Journal of antimicrobial chemotherapy 2005;56(1):1-5.
2005: Marta Boffito; Desmond Maitland; Laura Dickinson; David Back; Andrew Hill; Carl Fletcher; Graeme Moyle; Mark Nelson; Brian Gazzard; Anton Pozniak
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.
The Journal of antimicrobial chemotherapy 2005;55(4):542-5.
2005: Marta Boffito; Desmond Maitland; Yohan P Samarasinghe; Anton Pozniak
The pharmacokinetics of HIV protease inhibitor combinations.
Current opinion in infectious diseases 2005;18(1):1-7.
2005: Marta Boffito; Edward Acosta; David Burger; Courtney V Fletcher; Charles Flexner; Rodolphe Garaffo; Giorgio Gatti; Michael Kurowski; Carlo Federico Perno; Gilles Peytavin; Mario Regazzi; David Back
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs.
Antiviral therapy 2005;10(4):469-77.
2005: Marta Boffito; Edward Acosta; David Burger; Courtney V Fletcher; Charles Flexner; Rodolphe Garaffo; Giorgio Gatti; Michael Kurowski; Carlo Federico Perno; Gilles Peytavin; Mario Regazzi; David Back
Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy.
Antiviral therapy 2005;10(3):375-92.
2005: Marta Boffito; David Back; Meredith Stainsby-Tron; Andrew Hill; Giovanni Di Perri; Graeme Moyle; Mark Nelson; Jaqui Tomkins; Brian Gazzard; Anton Pozniak
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
British journal of clinical pharmacology 2005;59(1):38-42.
2004: Yohan P Samarasinghe; Marta Boffito; Giovanni Di Perri
Nucleoside/nucleotide reverse transcriptase inhibitor drug interactions.
Journal of HIV therapy 2004;9(4):79-86.
2004: Marta Boffito; Laura Dickinson; Andrew Hill; David Back; Graeme Moyle; Mark Nelson; Christopher Higgs; Carl Fletcher; Brian Gazzard; Anton Pozniak
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2004;37(3):1376-84.
2004: Akil Jackson; Stephen Taylor; Marta Boffito
Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors.
AIDS reviews 2004;6(4):208-17.
2004: Graeme Moyle; Marta Boffito
Unexpected drug interactions and adverse events with antiretroviral drugs.
Lancet 2004;364(9428):8-10.
2004: Lisa M Almond; Marta Boffito; Patrick G Hoggard; Stefano Bonora; Riccardo Raiteri; Helen E Reynolds; Silvia Garazzino; Alessandro Sinicco; Saye H Khoo; David J Back; Giovanni Di Perri
The relationship between nevirapine plasma concentrations and abnormal liver function tests.
AIDS research and human retroviruses 2004;20(7):716-22.
2004: Jennifer Ford; Marta Boffito; Adrian Wildfire; Andrew Hill; David Back; Saye Khoo; Mark Nelson; Graeme Moyle; Brian Gazzard; Anton Pozniak
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy 2004;48(7):2388-93.
2004: Marta Boffito; Michael Kurowski; Guido Kruse; Andrew Hill; Andrew A Benzie; Mark R Nelson; Graeme J Moyle; Brian G Gazzard; Anton L Pozniak
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.
AIDS (London, England) 2004;18(9):1291-7.
2004: Marta Boffito; Laura Dickinson; Andrew Hill; David Back; Graeme Moyle; Mark Nelson; Christopher Higgs; Carl Fletcher; Sundhiya Mandalia; Brian Gazzard; Anton Pozniak
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.
Antiviral therapy 2004;9(3):423-9.
2004: Marta Boffito; Graeme J Moyle
Can we boost enough without ritonavir?
The AIDS reader 2004;14(5):229-30, 233-5.
2004: Marta Boffito; Graeme J Moyle
Pharmacokinetic considerations for combining 2 protease inhibitors.
The AIDS reader 2004;14(3):110-2, 115-6.
2004: Stefano Bonora; Marta Boffito; Antonio D'Avolio; Mauro Sciandra; Anna Maria Caci; Francesca Conta; Alessandro Sinicco; francesco giuseppe de rosa; Giovanni Di Perri
Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine.
AIDS (London, England) 2004;18(3):577-8.
2004: Marta Boffito; Patrick G Hoggard; W Edward Lindup; Stefano Bonora; Alessandro Sinicco; Saye H Khoo; Giovanni Di Perri; David J Back
Lopinavir protein binding in vivo through the 12-hour dosing interval.
Therapeutic drug monitoring 2004;26(1):35-9.
2003: Marta Boffito; Stefano Bonora; Alessandro Sinicco; Riccardo Raiteri; Maria Grazia Milia; Saye H Khoo; Patrick G Hoggard; David J Back; Giovanni Di Perri
Treating advanced HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2003;34(3):344-5.
2003: Marta Boffito; Stefano Bonora; Paola Sales; Ivano Dal Conte; Alessandro Sinicco; Patrick G Hoggard; Saye Khoo; David J Back; Giovanni Di Perri
Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting.
AIDS research and human retroviruses 2003;19(10):941-2.
2003: Marta Boffito; David J Back; Terrence F Blaschke; Malcolm Rowland; Richard J Bertz; John G Gerber; Veronica Miller
Protein binding in antiretroviral therapies.
AIDS research and human retroviruses 2003;19(9):825-35.
2003: Stephen Taylor; Marta Boffito; Pietro L Vernazza
Antiretroviral therapy to reduce the sexual transmission of HIV.
Journal of HIV therapy 2003;8(3):55-66.
2003: Stefano Bonora; Gianluigi Zanusso; Riccardo Raiteri; Salvatore Monaco; Antonella Rossati; Sergio Ferrari; Marta Boffito; Sabrina Audagnotto; Alessandro Sinicco; Nicola Rizzuto; Ercole Concia; Giovanni Di Perri
Clearance of 14-3-3 protein from cerebrospinal fluid heralds the resolution of bacterial meningitis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;36(11):1492-5.
2003: Marta Boffito; David J Back; Patrick G Hoggard; Annamaria Caci; Stefano Bonora; Riccardo Raiteri; Alessandro Sinicco; Helen E Reynolds; Saye Khoo; Giovanni Di Perri
Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring.
AIDS (London, England) 2003;17(7):1107-8.
2003: Marta Boffito; Anna Lucchini; Agostino Maiello; Ivano Dal Conte; Patrick G Hoggard; David J Back; Giovanni Di Perri
Lopinavir/ritonavir absorption in a gastrectomized patient.
AIDS (London, England) 2003;17(1):136-7.
2002: Marta Boffito; Pierluigi Carriero; Laura Trentini; Riccardo Raiteri; Stefano Bonora; Alessandro Sinicco; Helen E Reynolds; Patrick G Hoggard; David J Back; Giovanni Di Perri
Pharmacokinetics of saquinavir co-administered with cimetidine.
The Journal of antimicrobial chemotherapy 2002;50(6):1081-4.
2002: Marta Boffito; Patrick G Hoggard; David J Back; Stefano Bonora; Agostino Maiello; Anna Lucchini; Giovanni Di Perri
Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with kaposi's sarcoma.
Antimicrobial agents and chemotherapy 2002;46(11):3684-5.
2002: Marta Boffito; Isabella Arnaudo; Riccardo Raiteri; Stefano Bonora; Alessandro Sinicco; Antonio Di Garbo; Helen E Reynolds; Patrick G Hoggard; David J Back; Giovanni Di Perri
Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.
AIDS (London, England) 2002;16(15):2081-3.
2002: Marta Boffito; John Tija; Helen E Reynolds; Patrick G Hoggard; Stefano Bonora; Giovanni Di Perri; David J Back
Simultaneous determination of rifampicin and efavirenz in plasma.
Therapeutic drug monitoring 2002;24(5):670-4.
2002: Marta Boffito; Patrick G Hoggard; Helen E Reynolds; Stefano Bonora; E Rhiannon Meaden; Alessandro Sinicco; Giovanni Di Perri; David J Back
The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.
British journal of clinical pharmacology 2002;54(3):262-8.
2002: Marta Boffito; Stefano Bonora; Riccardo Raiteri; Helen E Reynolds; Patrick G Hoggard; Alessandro Sinicco; David J Back; Giovanni Di Perri
Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting.
Therapeutic drug monitoring 2002;24(4):574-6.
2002: Marta Boffito; Katiusha Sciole; Riccardo Raiteri; Stefano Bonora; Patrick G Hoggard; David J Back; Giovanni Di Perri
Alpha 1-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(7):859-60.
2002: Marta Boffito; Antonella Rossati; Helen E Reynolds; Patrick G Hoggard; David J Back; Giovanni Di Perri
Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment.
AIDS research and human retroviruses 2002;18(5):341-2.
2002: Marta Boffito; Giorgio Marietti; Sabrina Audagnotto; Riccardo Raiter; Giovanni Di Perri
Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;34(4):558-9.